Incyte Corporation share price logo

Incyte Corporation Share Price

NASDAQ: INCY

Large Cap

$86.95

+0.97

(+1.13%)

as on

Incyte Corporation Stock Performance

as on September 4, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $86.15
    $87.44
    downward going graph

    0.92%

    Downside

    0.56%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $53.56
    $87.99
    downward going graph

    38.40%

    Downside

    1.20%

    Upside

    downward going graph

Incyte Corporation share price movements today

Previous Close
$85.98
Open
$86.15
Volume
951.8K
Day's Low - High
$86.15 - $87.44
52 Week Low - High
$53.56 - $87.99

Incyte Corporation Historical Returns

1 Month Return
+ 11.43 %
3 Month Return
+ 28.98 %
1 Year Return
+ 35.18 %
3 Year Return
+ 23.86 %
5 Year Return
-3.9 %

Incyte Corporation Stock Fundamentals & Key Indicators

Check Incyte Corporation market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$17.0B

EPS (TTM)

6.1116

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.07%

PE Ratio (TTM)

20.56

Industry PE ratio

-130.36

P/B Ratio

20.5579

PEG Ratio

0.1297

EBITDA

1.1B

Revenue (TTM)

4.6B

Profit Margin

18.99%

Return On Equity TTM

24.30%

Incyte Corporation Stock Valuation

Track how Incyte Corporation P/E has moved over time to understand its valuation trends.

Incyte Corporation in the last 5 years

  • Overview

  • Trends

Lowest (12.11x)

June 30, 2025

Industry (-130.36x)

September 4, 2025

Today (20.56x)

September 4, 2025

Highest (67.12x)

September 30, 2024

LowHigh

Today’s Price to Earnings Ratio: 20.56x

Incyte Corporation vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Incyte Corporation with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$17.0B-3.9%20.5618.99%
BUY$58.6B264.27%-505.15-12.96%
NA$39.4BNANA-3.89%
BUY$101.7BNA28.2531.86%
BUY$59.8B-2.85%14.2131.37%

Stock Returns calculator for Incyte Corporation Stock including INR - Dollar returns

The Incyte Corporation stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Incyte Corporation investment value today

Current value as on today

₹1,40,177

Returns

₹40,177

(+40.18%)

Returns from Incyte Corporation Stock

₹35,162 (+35.16%)

Dollar Returns*

₹5,014 (+5.01%)

Analyst Recommendation on Incyte Corporation Stock

Based on 29 analysts

BUY

55.17%

Buy

44.83%

Hold

0.00%

Sell

Based on 29 analysts, 55.17% of analysts recommend a 'BUY' rating for Incyte Corporation. Average target price of $81.7

Incyte Corporation Share Price Target

Get share price movements and forecasts by analysts on Incyte Corporation.

What analysts predicted

-6.43%DOWNSIDE

Target Price

$81.7

Current Price

$86.95

Analyzed by

29 Analysts

Target

$81.70

Incyte Corporation target price $81.7, a slight downside of -6.43% compared to current price of $86.95. According to 29 analysts rating.

Incyte Corporation Stock's Interest Amongst Investors

Search interest for Incyte Corporation Stock has increased by 66% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:66% versus previous 30 day period

Incyte Corporation Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
808
954
919
1,013
880
1,043
1,137
1,178
1,052
1,215
Gross Profit
751
886
858
943
819
950
1,051
1,090
979
1,136
Operating Income
90
193
214
187
91
-477
146
301
205
530
EBITDA
50
222
236
293
114
-367
179
336
257
581
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
19
20
21
21
21
22
22
22
22
22
Income Before Tax
51
277
233
270
236
-389
156
313
234
558
Income Tax Expense
30
74
62
69
66
54
50
112
75
153
Net Income
21
203
171
201
169
-444
106
201
158
404
Net Profit Margin
2.68%
21.32%
18.64%
19.84%
19.25%
-42.60%
9.36%
17.07%
15.03%
33.32%

Incyte Corporation Annual Profit & Loss

All numbers in Millions USD

Dec 2015
Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
753
1,105
1,536
1,881
2,158
2,666
2,986
3,394
3,695
4,241
Gross Profit
726
1,047
1,456
1,787
2,044
2,535
1,340
3,187
3,440
3,929
Operating Income
50
144
-243
129
402
-240
585
579
620
61
EBITDA
98
204
-253
209
475
-178
630
599
919
408
Interest Expense
45
38
6
1
1
2
1
2
2
2
Depreciation
-
-
52
54
54
51
57
67
79
89
Income Before Tax
7
107
-312
115
486
-232
570
529
834
316
Income Tax Expense
1
3
0
5
39
63
-378
188
236
284
Net Income
6
104
-313
109
446
-295
948
340
597
32
Net Profit Margin
0.87%
9.43%
-20.38%
5.82%
20.70%
-11.09%
31.76%
10.04%
16.17%
0.77%

Incyte Corporation Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
203
171
201
169
-444
106
201
158
404
Operating Cash Flow
306
147
147
218
-575
310
381
266
44
Investing Cash Flow
-7
-17
-154
-73
213
38
-21
1
-18
Financing Cash Flow
12
-37
0
-12
-1,997
-32
20
-12
-11
Change in Cash
310
96
-13
132
-2,358
316
383
253
13

Incyte Corporation Annual Cash Flow

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
104
-313
109
446
-295
948
340
597
32
Operating Cash Flow
304
-92
336
710
-124
749
969
496
335
Investing Cash Flow
-232
-349
-86
-87
-269
-207
-78
-207
157
Financing Cash Flow
58
690
14
45
71
6
0
-20
-2,021
Change in Cash
130
247
264
668
-318
544
893
262
-1,525

Global Institutional Holdings in Incyte Corporation

Funds
Holdings
Baker Bros Advisors LP
15.74%
Vanguard Group Inc
10.24%
BlackRock Inc
8.93%
Dodge & Cox
7.61%
State Street Corp
5.14%

Incyte Corporation News & Key Events

  • img

    Today's Timeline - 22 August

    Fri, 07:09 PM

    -

    Eli Lilly and Incyte's Olumiant approved for rheumatoid arthritis and alopecia areata, generating $475.2 million in sales.

    Fri, 09:38 PM

    -

    Incyte updates clinical study on ruxolitinib for myelofibrosis, aiming to establish a safe starting dose.

Insights on Incyte Corporation

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, INCY stock has moved up by 3.9%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 158.20M → 404.99M (in $), with an average increase of 60.9% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 1.05B → 1.21B (in $), with an average increase of 13.4% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 101.7% return, outperforming this stock by 77.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Beone Medicines Ltd has given 78.4% return, outperforming this stock by 43.2%

About Incyte Corporation

incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
OrganisationIncyte Corporation
Headquarters1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
IndustryHealth Technology
CEOMr. Herve Hoppenot
E-voting on sharesClick here to vote

Key Management of Incyte Corporation

Name

Title

Mr. Herve Hoppenot

Advisor to CEO & Director

Mr. Thomas Tray

VP of Finance, Chief Accounting Officer & Controller

Ms. Sheila A. Denton J.D.

Executive VP, General Counsel & Corporate Secretary

Ms. Pamela M. Murphy

Vice President of Investor Relations & Corporate Communications

Mr. Michael James Morrissey

Executive VP & Head of Global Technical Operations

Greg Shertzer

Senior Director of Investor Relations

Dr. Pablo J. Cagnoni M.D., Ph.D.

President and Head of Research & Development

Ms. Christiana Stamoulis M.B.A.

Executive VP & CFO

Dr. Steven H. Stein M.D.

Executive VP & Chief Medical Officer

Mr. William Meury

CEO, President & Director

FAQs

What is Incyte Corporation share price today?

Incyte Corporation share price today is $86.95 as on at the close of the market. Incyte Corporation share today touched a day high of $87.44 and a low of $86.15.

What is the 52 week high and 52 week low for Incyte Corporation share?

Incyte Corporation share touched a 52 week high of $87.99 on and a 52 week low of $53.56 on . Incyte Corporation stock price today i.e. is closed at $86.95,which is 1.18% down from its 52 week high and 62.34% up from its 52 week low.

What is Incyte Corporation's market capitalisation today?

Incyte Corporation market capitalisation is $0.02T as on .

How to invest in Incyte Corporation Stock (INCY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Incyte Corporation on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Incyte Corporation Shares that will get you 0.0173 shares as per Incyte Corporation share price of $86.95 per share as on September 4, 2025 at 1:29 am IST.

What is the minimum amount required to buy Incyte Corporation Stock (INCY) from India?

Indian investors can start investing in Incyte Corporation (INCY) shares with as little as ₹88.115 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.15 in Incyte Corporation stock (as per the Rupee-Dollar exchange rate as on ). Based on Incyte Corporation share’s latest price of $86.95 as on September 4, 2025 at 1:29 am IST, you will get 0.1150 shares of Incyte Corporation. Learn more about fractional shares .

What are the returns that Incyte Corporation has given to Indian investors in the last 5 years?

Incyte Corporation stock has given -3.9% share price returns and 20.11% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?